We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Partnership to Simplify Complex DNA Microarray Analyses

By LabMedica International staff writers
Posted on 14 Jul 2011
A partnership between American and British biotech companies will automate and simplify the complex and error-prone manual steps previously required for performing DNA microarray analyses.

BlueGnome (Cambridge, United Kingdom) has announced the signing of a supply agreement with SciGene (Sunnyvale, CA, USA). More...
SciGene will manufacture BlueGnome’s new range of ClearHyb hybridization and wash systems.

Previously SciGene had noted that BlueGnome’s recommended manual labeling, hybridization, and posthybridization processing methods for its CytoChip test required a collection of laboratory equipment and supplies including staining dishes, slide boxes, stirrers, Coplin jars, a water bath, and an oven that need to be collected, cleaned, and assembled for each run. Once set up, the procedure was technically challenging with many handling steps including the use of seven different washes with careful monitoring of buffer temperatures. The complexity of the methods provided multiple entry points for variability that could lead to ambiguous patient results and a higher cost per test.

The new partnership was designed to eliminate this ambiguity by automating and simplifying the complex and error-prone manual steps from sample preparation through slide processing for improved test reliability and lowered cost.

Nick Haan, CEO of BlueGnome, said, “Time to market is a major issue for new laboratories that wish to establish and evolve their microarray-based services. With sales to 39 countries so far this year, we find that new laboratories are increasingly looking for a complete turnkey solution, including laboratory hardware, which enables their newly trained scientists to deliver the highest quality results in the shortest possible timeframe. We have long recommended SciGene products as the best available solution for hybridization and washing of our microarrays and are excited to be working with them to strengthen this relationship with new ClearHyb products.”

Dr. Jim Stanchfield, president and CEO of SciGene, said, “We are pleased with our partnership whereby SciGene technology will be used to simplify the microarray workflow used with BlueGnome’s array solutions that will enhance the reproducibility of these assays and their customers’ laboratory productivity.”

Related Links:
BlueGnome
SciGene


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.